Algitrin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Algitrin

Property Description
Active Ingredients Acetaminophen, Ibuprofen
Form Oral Tablet (Film-Coated)
Pharmacological Class Analgesic, NSAID Combination
General Purpose Relief of pain and fever
Origin Synthetic

Algitrin is a commercially available fixed-dose combination product designed for oral administration. It is identified by its two distinct, synthetic active ingredients: Acetaminophen (or Paracetamol) and Ibuprofen. This medicine is presented as a single film-coated tablet, ensuring simultaneous delivery of the compounds. Acetaminophen functions as a central analgesic and antipyretic, combined with Ibuprofen, which is classified as a propionic acid derivative and Nonsteroidal Anti-inflammatory Drug (NSAID). The integration of these two established agents into one dosage form is designed to enhance patient convenience and therapeutic synergy.

Pharmacological Classification and General Purpose

Algitrin is classified as an Analgesic and NSAID combination, defining its dual pharmacological action. The primary purpose is to provide symptomatic relief for mild to moderate pain and to aid in reducing fever (pyrexia). For instance, this combination is typically used for the temporary relief of common painful conditions such as headache or dental pain. Clinical data indicates the effectiveness of combining the two ingredients, which can offer improved relief profiles compared to utilizing either drug alone.

The Dual Action Principle

The unique identity of Algitrin is rooted in its dual action principle, where the two ingredients address discomfort through complementary physiological actions. Acetaminophen modulates the perception of pain by acting predominantly in the Central Nervous System (CNS) to elevate the overall pain threshold. Conversely, Ibuprofen inhibits cyclooxygenase (COX) enzymes peripherally, thereby reducing the synthesis of prostaglandins—the chemical mediators that drive inflammation and sensitize pain receptors. This combined therapeutic strategy is integral to the product’s design, offering a comprehensive, non-opioid approach to managing discomfort.

What side effects are possible with Algitrin?

Possible Side Effects and Safety Information

The safety profile for this combination of Acetaminophen and Ibuprofen is based on the documented adverse reactions for each component as classified by regulatory authorities. Side effects are systematically grouped by the organ system affected and categorized by frequency of occurrence in official documents.


Frequency-Classified Adverse Reactions

Adverse reactions are formally ranked based on clinical data, with the most common generally involving the digestive and nervous systems:

  • Common: Adverse events frequently reported include dyspepsia (indigestion), nausea, abdominal pain, headache, and dizziness.
  • Uncommon: Less frequently reported effects include vomiting, flatulence, diarrhea, and gastrointestinal ulceration.
  • Very Rare: These include severe reactions such as serious skin disorders (e.g., Stevens-Johnson Syndrome) and acute renal failure.

Serious Adverse Reaction Risks

The official labeling highlights several serious risks associated with the active ingredients. The NSAID component (Ibuprofen) is associated with an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, and severe gastrointestinal events such as bleeding and perforation. Acetaminophen is linked to the risk of severe hepatic failure, which can be fatal. The risk of these serious gastrointestinal and cardiovascular events is noted to increase with the duration of use.


Population-Specific Safety Constraints

Official documents outline specific safety considerations for certain patient groups. Older adults may have an increased risk of serious gastrointestinal events. The medicine is contraindicated in individuals with severe hepatic failure, severe renal failure, or severe heart failure, or a history of active peptic ulcer.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Algitrin, a combination of Acetaminophen and Ibuprofen, is defined by the distinct toxicological risks of both components, with potential for severe and fatal outcomes.

Overdose Manifestations and Severe Outcomes

Documented signs of overdose, which may appear immediately or be delayed for days, include nausea, vomiting, abdominal pain, loss of appetite, and paleness. Overdose can escalate to severe and life-threatening conditions involving critical body systems:

System Affected Severe Outcomes Documented in Labeling
Hepatic Severe Liver Damage / Acute Liver Failure (Acetaminophen component)
Cardiovascular Risk of Fatal Thrombotic Events (Ibuprofen/NSAID component)
Gastrointestinal Severe Bleeding, Ulceration, or Perforation
Renal Kidney Failure

Mandatory Emergency Actions

Seek emergency medical attention or contact a Poison Control Center right away. Prompt medical attention is critical even if no signs or symptoms are present, due to the potential for delayed onset of liver damage from the acetaminophen component.

Overdose Management Notes

The specific antidote for acetaminophen toxicity is N-acetylcysteine (NAC), which must be administered according to official protocols. Supportive management may include the use of activated charcoal or gastric lavage. Laboratory monitoring, including measurement of serum acetaminophen concentration and hepatic function, is required. Individuals with pre-existing liver disease or those who consume three or more alcoholic drinks daily have a documented increased risk of severe liver damage.

Therapeutic Uses of Algitrin

Quick Facts: Algitrin

  • May be used for: Temporary relief of mild to moderate pain.
  • Therapeutic areas include: Headache, dental pain, and musculoskeletal discomfort.
  • Potential application: Reducing fever in self-limiting conditions.
  • Additional use: Addressing pain and discomfort associated with menstruation.

What Algitrin Treats: Main Uses and Benefits

Algitrin is a medicinal product intended for the temporary management of symptoms related to mild to moderate discomfort. Its application is centered on influencing the perception of pain and assisting in the process of temperature regulation.

The core therapeutic domains where Algitrin may be useful include providing relief from several common sources of pain. These encompass headache, dental pain, and various forms of musculoskeletal discomfort, such as back pain (lumbalgia) and muscle aches.

Furthermore, this product may be employed to manage pain and inflammation that is associated with menstruation. It also has an indicated use for contributing to the reduction of fever in conditions that are temporary and self-limiting, provided the fever does not persist for more than three days.

Algitrin can assist individuals seeking to address discomfort related to moderate joint pain associated with conditions like osteoarthritis.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Algitrin — Official Regulatory Information

This section outlines the officially documented eligibility and non-eligibility for Algitrin, based strictly on government regulatory documents.

Category Eligibility Status (as stated in label)
Populations for whom use is allowed Generally permitted for Adults and Adolescents (typically 12 years and older) who do not meet any contraindication criteria.
Populations for whom use is contraindicated Patients with known allergy to Acetaminophen, Ibuprofen, or any other NSAID (including aspirin). Those with severe liver damage or severe kidney damage must not use this medicine. It is also contraindicated for patients with severe heart failure or a history of active GI bleeding/ulcers.
Age-related eligibility rules Children under 12 years of age are generally classified as a population where use is not established or not recommended. Older adults should use with caution due to higher risk of serious adverse events.
Pregnancy and lactation eligibility status Use is contraindicated from 20 weeks gestation and later due to the NSAID component's risk of fetal harm. For breastfeeding, individuals should consult a health professional before use.
Eligibility-related restrictions Must NOT be used with any other product containing Acetaminophen (due to toxicity risk) or for pain right before or after Coronary Artery Bypass Graft (CABG) surgery.

Regulatory documents define eligibility based on absolute prohibitions (contraindications) related to the active ingredients' known risks: NSAID toxicity and Acetaminophen hepatotoxicity. Use is further constrained by age-group restrictions and physiological states, strictly as determined by official labeling.

What should I know about interactions with other medicines?

Algitrin is a fixed-dose combination product whose interaction profile is determined by the regulatory constraints associated with Acetaminophen and Ibuprofen. Officially documented interaction patterns involve drug-drug, drug-substance, and administration-timing constraints, all established in government labeling.

Documented Interaction Patterns

Interaction Type Interacting Substances/Classes Formal Regulatory Outcome
Contraindicated Combinations Other NSAIDs (e.g., selective COX-2 inhibitors), Acetaminophen-containing products Co-administration is strictly prohibited due to additive risks (e.g., gastrointestinal bleeding, hepatotoxicity).
Pharmacodynamic Anticoagulants (e.g., Warfarin), Antiplatelet agents, SSRIs Officially documented increased risk of bleeding due to synergistic effect.
Pharmacokinetic Lithium, Digoxin, Methotrexate Ibuprofen component reduces renal clearance, leading to documented increased plasma concentrations of the co-administered drug.
Timing-Based Rule Low-dose Aspirin (for cardioprophylaxis) Must be administered at least 8 hours before or 30 minutes after Ibuprofen to avoid interference with antiplatelet effect.

Interactions with Lifestyle Substances: Chronic high intake of Alcohol is an officially documented risk factor for severe Acetaminophen-induced hepatotoxicity. Furthermore, the Ibuprofen component may reduce the antihypertensive effect of Diuretics, ACE inhibitors, and ARBs, an interaction noted to be of greater concern in the elderly population.

Mechanism of Action

How Algitrin Works: Pharmacodynamic Mechanism

Algitrin’s mechanism is defined by a synergistic dual-site blockade of nociceptive and thermoregulatory signaling pathways, integrating two distinct yet complementary modes of action—one primarily peripheral, the other central.


Non-Selective Cyclooxygenase Inhibition

The Ibuprofen component exerts a non-selective, reversible inhibitory effect on the Cyclooxygenase ( COX-1 and COX-2) enzymes. This molecular action blocks the Arachidonic Acid Cascade, thereby reducing the synthesis of Prostaglandin E2 ( PGE2) and other inflammatory mediators at the site of tissue injury, a process that reduces the sensitization of peripheral nociceptors.


Central Pain and Thermoregulation Modulation

Acetaminophen’s action is mainly central, involving COX inhibition within the CNS and potential modulation of CB1 and TRPV1 receptors via its metabolite. This multi-modal action in the brain and spinal cord directly elevates the pain perception threshold and efficiently resets the hypothalamic thermoregulatory center, promoting heat dissipation consistent with the reduction of an elevated thermal set point.


Mechanistic Dual-Site Synergy

The combination achieves synergy because Ibuprofen targets the generation of inflammatory mediators peripherally, while Acetaminophen targets the processing of nociceptive signals centrally. This dual-site blockade modulates the pain pathway at both the peripheral and central levels, facilitating a broader physiological modulation of nociceptive signaling than either mechanism achieves independently.

Dosage and Administration Information

How Algitrin is Used: Official Administration Guidelines

The usage protocol for the fixed-dose combination product Algitrin is defined by specific parameters for dosing, frequency, and administration constraints. These parameters provide the framework for the product's intended application.

Administration Scope

Field Official Instruction
Route of administration The medicine is approved only for the oral route, administered as a film-coated tablet or caplet.
Dosing schedule (Adults ge 12 years) The standard dose is typically two caplets (Acetaminophen 250 mg / Ibuprofen 125 mg strength) or three tablets (Acetaminophen 325 mg / Ibuprofen 97.5 mg strength), depending on the specific product formulation.
Timing in relation to meals The product may be taken with food or milk to aid in gastric tolerance, or without.
Age-group administration rules Not authorized for use in children under 12 years of age unless the dose is expressly determined and directed by a healthcare professional.
Special procedural conditions The medicine must not be taken with any other prescription or nonprescription product that contains acetaminophen.

Use Protocol and Dosing Boundaries

The regimen for this combination product is based on as-needed (PRN) use for symptoms. Dosing must maintain a minimum time interval of 6 to 8 hours between each administration, depending on the specific product strength. The usage is defined for short-term purposes only, and the maximum recommended daily intake must not be exceeded (e.g., 6 caplets in 24 hours for the 250 mg/125 mg FDC). This protocol structures the use around single, intermittent oral doses taken within clearly defined time and quantity constraints.

Recent Clinical Evidence

Research evidence / Overview of studies for Algitrin


Evidence for Acute Pain Relief and Efficacy Studies

The primary body of clinical research for this combination was evaluated in settings involving acute, high-intensity discomfort, such as the postoperative pain model. This research includes Randomized Controlled Trials (RCTs) and Systematic Reviews that examined short-term outcomes related to physical discomfort in adults and adolescents who were experiencing conditions associated with acute or disruptive episodes. The research focused on standardized metrics, such as how quickly an outcome was observed and the total measured change in pain intensity over a short period.

The findings describe patterns observed in the studies related to measured pain outcomes associated with the combination versus groups receiving individual components or a placebo. Regulatory evaluations described the evidence as consistent across several trials that examined the postoperative pain model. However, the follow-up durations were limited, as the research was designed to explore short-term symptom patterns in these specific, acute scenarios.


Evidence for Fever Outcomes (Antipyretic Studies)

The combination was studied for outcomes related to systemic or functional imbalance, specifically fever outcomes. This research includes Controlled Trials and Pharmacokinetic studies that measured physiological strain or stress in the body. These studies mainly included healthy adults and some pediatric populations, researching temporary physiological imbalance.

The research describes observations on how symptoms evolved in the observed populations, particularly the rate and measured reduction in core body temperature, typically over assessment periods of four to eight hours. These findings contribute to understanding the short-term measurements of temperature control. However, the overall evidence is limited regarding the outcomes of the combination in dedicated trials focusing only on fever, compared to the number of pain-focused studies. Data show patterns related to short-term changes after a single dose, but certainty remains low regarding outcomes after continuous use.


Research Gaps and Areas of Uncertainty

This body of research, while providing short-term context, contains several limitations. Long-term effects are not fully established because follow-up durations were limited. Data for certain groups remain insufficient, including findings related to patients with specific chronic comorbidities and dedicated information for older adults. This research provides context but not individual predictions; the findings describe group patterns, not personal outcomes. Study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly outside of those controlled settings.

Frequently Asked Questions (FAQ)

Common questions about Algitrin (FAQ)


Q: How is Algitrin different from other common over-the-counter or prescription medicines?

Official documents describe Algitrin as a fixed-dose combination that contains two different pain-relieving ingredients: an NSAID (Ibuprofen) and Acetaminophen. This dual composition is designed to address pain using two complementary methods at the same time. This combined action affects pain signaling in both the central and peripheral nervous systems, which is a characteristic that differentiates it from medicines that contain only one active ingredient.


Q: Will I feel the effect of Algitrin immediately after taking it?

According to official pharmacokinetic studies, the active components typically reach their highest concentration in the bloodstream within a relatively short period after administration. This suggests that the effects may begin relatively quickly after the first dose. Specific time frames often fall between 30 and 90 minutes.


Q: Does Algitrin have a black box warning described in official documents?

Yes, the official prescribing information for the ingredients in this product contains a Boxed Warning, which is the strongest regulatory caution. This warning concerns the risk of serious cardiovascular thrombotic events (like heart attack and stroke) and severe gastrointestinal events (such as bleeding and perforation). It also highlights the risk of severe liver damage from the acetaminophen component.


Q: Are there any specific foods or drinks that should be avoided while taking Algitrin?

Official labeling cautions that combining this medicine with chronic high intake of alcohol can substantially increase the risk of severe liver damage. Beyond alcohol, official documents do not commonly prohibit specific non-alcoholic foods or drinks. The medicine may be taken with food or milk to help with gastric comfort.


Q: I read that Algitrin affects certain enzymes; what does that mean in simple terms?

The official documents explain that the medicine works through a dual mechanism. The Ibuprofen component works outside the brain, where it helps stop the body from producing pain-causing chemicals related to inflammation. The Acetaminophen component works mainly in the central nervous system (brain and spinal cord) to raise the point at which pain is felt, providing comprehensive relief.


Q: Can Algitrin affect my ability to drive or operate machinery?

Official warnings indicate caution may be necessary. The potential for side effects, such as dizziness or drowsiness (somnolence), is noted in the official documentation, which suggests it may affect the ability to operate machinery.


Q: What counts as an allergic reaction to Algitrin?

Official safety information describes signs (hives, rash, facial swelling, difficulty breathing) that may require immediate medical attention and discontinuation. The official documents note that severe skin reactions, such as blistering, are classified as very rare but serious adverse events.


Q: Do different doses of Algitrin have different side effects?

Official prescribing information indicates that the risk of certain serious side effects can increase with higher doses and longer duration of use. Specifically, the risk of serious gastrointestinal bleeding and cardiovascular events is noted to be related to the amount taken.


Q: Is it normal to feel a change in energy level when starting Algitrin?

While not always classified as a common occurrence, certain central nervous system (CNS)-related effects are listed among the possible reported side effects in official documents. These include fatigue or somnolence (drowsiness). These effects are potential adverse reactions noted in the official documentation.


Q: Is Algitrin known to cause issues with sleep?

Official documents sometimes list potential side effects that can affect sleep patterns. These include insomnia (difficulty sleeping) or, conversely, somnolence (drowsiness). These effects are typically ranked as uncommon or rare in the comprehensive list of adverse events.


Q: What happens if I forget to take Algitrin one day?

Since this medicine is typically taken as needed for temporary pain relief, official patient guidance emphasizes adhering to the minimum required time interval between doses. If a dose is forgotten, it is recommended to take it only if the next dose is not due for several hours. Regulatory documents state that a double dose must not be taken.


Q: Do any official sources mention Algitrin causing changes in weight?

Official safety documents for the active ingredients sometimes include effects related to fluid retention or metabolism. Among the comprehensive list of possible adverse events, edema (fluid retention) or, less frequently, unexplained changes in weight are occasionally mentioned.


Q: How often do official sources recommend reviewing my use of Algitrin?

Official labeling advises that the medicine is for short-term, temporary relief only. If symptoms persist beyond the short-term duration defined in the label (e.g., 3 days for fever or 10 days for pain), the official guidance recommends seeking review by a healthcare professional.


Q: Is Algitrin habit-forming or described as having abuse potential?

Official regulatory documents, including the Drug Abuse and Dependence section, indicate that this medicine is a non-opioid combination product. As such, it is not associated with dependence, withdrawal effects, or abuse potential.


Q: Why does Algitrin have specific instructions about how to stop taking it?

Because the medicine is intended for short-term use for temporary symptoms, official guidance advises that treatment should be stopped once the symptoms are resolved or if adverse effects occur. Specific instructions for cessation, such as tapering, are generally not required because it is not a drug that causes physical withdrawal upon stopping.


Q: How should I keep track of side effects when using Algitrin?

The regulatory guidance highlights specific serious adverse effects that require immediate medical attention, such as signs of stomach bleeding (e.g., black stools) or severe allergic reactions. If any serious or unexpected reactions occur, immediate medical care is recommended.

How should Algitrin be stored and disposed of?

How to Store and Dispose of Algitrin

The storage and disposal of Algitrin (Acetaminophen/Ibuprofen) must follow regulatory requirements to maintain product quality and safety.

Storage Requirements

Algitrin tablets must be stored at room temperature, typically between 15 C and 30 C. It is mandatory to keep the medicine in its original container with the lid tightly closed and to protect the tablets from moisture and direct light. The product must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Expired or unused Algitrin should be disposed of according to local guidelines, preferably through an approved drug take-back program. If no take-back program is available, the medicine should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag, and discarded in the household trash. It must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Algitrin found in:

A-Z Index: